Global sales and Copaxone lift Teva
This article was originally published in Scrip
Executive Summary
In reviewing its financial results for the year, Teva Pharmaceutical Industries' chief executive Shlomo Yanai called 2010 "a great year for Teva", in which the firm became the generics leader in Europe, moved to complete its integration of the German company Ratiopharm, increased its presence in emerging markets, and had record sales of its multiple sclerosis drug Copaxone (glatiramer acetate).